Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 9, 2025ACS Infectious Diseases

Targeting Mycolic Acid Biosynthesis with Cyclic Sulfamates: A New Strategy against Mycobacterium tuberculosis

View Full Paper
Ask AI
Bookmark
Share

Authors

PHPriscila Cristina Bartolomeu HalickiJKJed KimAGAmory F Griffin

Discussion

Loading...

Member takes

Overview

Testing cyclic sulfamate compounds reveals potent antimycobacterial activity against Mycobacterium tuberculosis, suggesting new treatment options.

Key Points

  • Cyclic sulfamate compounds demonstrated potent activity against Mycobacterium tuberculosis, highlighting a novel treatment strategy.
  • Evidence shows that these compounds target KasA, inhibiting the essential mycolic acid biosynthesis pathway in Mtb.
  • Whole genome sequencing of resistant mutants supports the unique mechanism of action employed by cyclic sulfamates.
  • This novel approach could lead to the development of alternative treatment options for tuberculosis.

Cite This Study

Halicki et al. (2025) studied this question.

synapsesocial.com/papers/68e70db290569dd607ee625chttps://doi.org/10.1021/acsinfecdis.5c00419
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Structural features, activity relationships, and synthetic strategies of indole-based derivatives as antitubercular agents targeting mycolic acid biosynthesis2026
  2. 2Physiological modeling of the metaverse of the Mycobacterium tuberculosis β-CA inhibition mechanism2024 · 4 citations
  3. 3Halting Tuberculosis in Its Tracks: Advances and Strategies for Discovering Therapeutic Targets in <i>Mycobacterium tuberculosis</i>2026
  4. 4Discovery of benzo[c]phenanthridine derivatives with potent activity against multidrug-resistant <i>Mycobacterium tuberculosis</i>2024 · 1 citations
  5. 5Combating Drug Resistance in <i>Mycobacterium Tuberculosis</i> : A Combinatorial in Silico and Experimental Modeling Approach Toward Novel ATP Synthase Inhibitor Discovery2026